Medtronic Shares Plunge to New 52-Week Low at $73.31

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 73.31 as of June 2, 2026. This decline marks a significant downturn for the stock, which has experienced a 1-year performance drop of 11.29%, contrasting sharply with the S&P 500's gain of 28.2% during the same period. The company's market capitalization stands at USD 113,290 million, categorizing it as a large-cap entity. Medtronic's price-to-earnings (P/E) ratio is currently at 20.00, while its dividend yield is noted at 3.20%. The firm maintains a debt-to-equity ratio of 0.43, indicating a relatively low level of debt compared to equity. Despite the recent price decline, Medtronic has shown some positive financial metrics, including a robust operating cash flow of USD 7,146 million and a return on capital employed (ROCE) of 9.72%. The stock's performance has been characterized by high institutional holdings at 86.93%, reflecting confidence from larger investors in the company's fundamentals.